STUDY

Tranexamic acid pills faded melasma 49%, vs 18% with a dummy pill

“Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma.” Del Rosario E et al. Journal of the American Academy of Dermatology. February 2018

Del Rosario E et al. · Journal of the American Academy of Dermatology · February 2018

Randomized placebo-controlled trial
The finding

After three months, melasma scores fell 49% with oral tranexamic acid plus sunscreen and 18% with placebo plus sunscreen in a small randomized trial.

Type of study

Where this study sits on the evidence spectrum

Some kinds of studies are much more reliable than others. Studies further right do more to rule out chance and bias.

Weaker evidenceStronger evidence
Lab or animal studyCase reportCase seriesCohort studyRandomized trialMeta-analysis
Randomized and double-blind. Everyone used sunscreen, and participants received either an active capsule or a matching placebo.
At a glance

Who was studied and for how long

Enrolled
44 people
39 completed the study
Treatment
3 months
Then 3 months with sunscreen only
Condition
Moderate to severe melasma
One study center
Compared
Capsule vs placebo
Both groups used sunscreen
What they did

How the study worked

44 peoplemelasmaRANDOMSPLITTranexamic acid250 mgtwice dailyPlacebodummy capsuletwice dailyMEASURED AT3 and 6 monthsmelasma score44 peoplemelasmaRANDOMSPLITTranexamic acid250 mg · twice dailyPlacebodummy capsule · twice dailyMEASURED AT3 and 6 monthsmelasma score
Random assignmentParticipants received tranexamic acid or placebo.
Take capsulesFor three months, participants took 250 mg of tranexamic acid or placebo twice daily and used sunscreen.
Follow after stoppingBoth groups continued sunscreen alone for another three months.
What they found

The results

Tranexamic acidPlacebo

Drop in melasma score at 3 months

Change from baseline at the end of capsule treatment.

Tranexamic acid
49%
Placebo
18%

Drop in melasma score at 6 months

Change from baseline three months after both groups stopped capsules.

Tranexamic acid group
26%
Placebo group
19%
The gap was larger during treatment and narrowed after the capsules stopped. No serious adverse events were reported, but a study this small cannot rule out rare harms.
Who paid for it

Funding and conflicts of interest

The article lists no funding source.

How much to trust it

Strengths and limits

Strengths

  • Randomized and double-blind
  • Both groups used sunscreen
  • Measured melasma again after capsules stopped

Limits

  • Small: 44 enrolled and 39 completed
  • One center, with mostly Hispanic women enrolled
  • Only three months of treatment and three months of follow-up
  • Compared with placebo plus sunscreen; did not compare with prescription creams
Moderate confidence. The placebo comparison supports a short-term effect, but the sample was small and the gap narrowed after treatment stopped.
What it means for you

The takeaway

Bigger change during treatment

Adding oral tranexamic acid to sunscreen lowered melasma scores more during treatment. The difference was smaller three months after stopping.

The trial was too small to assess rare risks such as blood clots.

Terms in this study

Words worth knowing

Melasma

Dark patches of skin, most often on the face.

mMASI

A score that combines how much of the face is affected and how dark the patches are.

Placebo

A dummy capsule without the active drug.

Original source

Del Rosario E, Florez-Pollack S, Zapata L, Hernandez K, Tovar-Garza A, Rodrigues M, Hynan LS, Pandya AG. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma.. J Am Acad Dermatol. 2018;78(2):363-369.

PMID 28987494